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Abstract
Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  severe  disease,  potentially  fatal,  if  not 
diagnosed  and  treated  promptly.  TTP  is  clinically  characterized  by  the  pentad  o
thrombocytopenia,  Coombs-negative  hemolytic  anemia,  fever,  renal  abnormalities  and 
neurological  disturbances.  Advances  in  recent  years  have  delineated  the  molecular 
mechanisms of acquired and hereditary TTP.
Many  infectious  organisms  have  been  reported  t
mycoplasma, but few cases of Brucella
have been reported.
We describe a young woman who presented with TTP after acute infection with both 
melitensis  and  Brucella  abortus.  The  patient  completely  recovered  following  aggressive 
therapy  with  plasmapharesis,  high
therapy.
Since measurement of ADAMTS13 activity and neutralizing antibodies is now available, and 
none  of  the  reported  cases  of  brucellosis  with  thrombotic  microangiopathy  (including  the 
present report) were tested, for better understanding of this rare association, we recommend 
this work-up in future cases.  
Introduction: Thrombotic  thrombocytopenic 
purpura (TTP) was first described by Moschowitz 
in 1925.
1 Since then, various infections have been 
reported  to  be  associated  with  TTP.  Acute 
Brucellosis is rarely associated with TTP, and has 
been reported only in a few cases.
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Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  severe  disease,  potentially  fatal,  if  not 
diagnosed  and  treated  promptly.  TTP  is  clinically  characterized  by  the  pentad  o
negative  hemolytic  anemia,  fever,  renal  abnormalities  and 
neurological  disturbances.  Advances  in  recent  years  have  delineated  the  molecular 
mechanisms of acquired and hereditary TTP.
Many  infectious  organisms  have  been  reported  to  be  associated  with  TTP,  especially 
Brucella infection associated with thrombotic microangiopathy 
We describe a young woman who presented with TTP after acute infection with both 
.  The  patient  completely  recovered  following  aggressive 
therapy  with  plasmapharesis,  high-dose  corticosteroids  and  appropriate  antimicrobial 
Since measurement of ADAMTS13 activity and neutralizing antibodies is now available, and 
one  of  the  reported  cases  of  brucellosis  with  thrombotic  microangiopathy  (including  the 
present report) were tested, for better understanding of this rare association, we recommend 
Thrombotic  thrombocytopenic 
purpura (TTP) was first described by Moschowitz 
Since then, various infections have been 
reported  to  be  associated  with  TTP.  Acute 
with TTP, and has 
Case  report: A  27  year-old  previously  healthy 
female,  was  admitted  after  three  days  abdominal 
pain,  vomiting,  headache,  general  malaise,  and 
fever since the night prior to admission. Two weeks 
earlier, the patient noticed red urine and excessive 
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gum  bleeding  during  teeth  brushing.  No 
medications  were  used. Physical  examination 
revealed low grade fever of 37.8
oC, blood pressure 
121/54 mmHg, and a regular heart rate of 54/min. 
There  were  some  purpura  on her  legs,  back  and 
breast, a moderate splenomegaly and mild jaundice. 
Fundus examination was normal.
Laboratory  tests  at  admission  showed 
hemoglobin: 9.9 g/dl, white blood cells: 5.4 x10
9/L,  
platelets: 7 x10
9/L, and reticulocyte counts: 2.7%. 
Peripheral blood smear presenteded red blood cell 
fragmentation (schistocytes).
Lactate  dehydrogenase  was  3,046  IU/L, 
aspartate  aminotransferase  153  IU/L,  gamma-
glutamyl transferase 39 IU/L, alkaline phosphatase 
138 IU/L, total bilirubin 6.6 mg/dl, direct bilirubin 
2.5mg/dl. Blood urea nitrogen and creatinine were 
within normal limits. 
Urinalysis  showed  hematuria  and 
hemoglobinuria.  Coagulation  screening  tests  were 
normal,  fibrinogen  degradation  products  (FDG) 
were  increased  (over  492mg/dl).  Bone-marrow 
aspirate  showed  active  hematopoiesis  without 
blasts.
Viral serology tests, including hepatitis B virus, 
hepatitis  C  virus,  Epstein-Bar  virus,  cyto-megalo 
virus and parvo virus were all negative, as well as 
anti-nuclear antibodies, anti double-stranded DNA, 
anti  Sm  and  anti  RNP.  C3  and  C4  levels  were 
normal. Chest x-ray was normal, while abdominal 
ultra-sound showed moderate splenomegaly.
A diagnosis of TTP was made, and treatment 
with  intravenous  methylprednisolone  was  started, 
but the hemoglobin continued to drop to levels of 
5.9  mg/dl  without  significant  improvement  in  the 
platelet  count,  which  entitled  red  blood  cell  and 
platelet  transfusions.  Plasma-exchange  was 
performed for 9 days with significant improvement 
in platelets and hemoglobin levels.
On  the  8
th day  after  admission,  blood  culture 
yielded Brucella.  Brucella agglutination titer was 
positive  for  two  strains:  1/320  for  both  Brucella 
melitensis and Brucella abortus . Blood culture was 
repeatedly positive for Brucella. A second Brucella
agglutination  titer  was  1/1,280  for  Brucella 
melitensis  and  1/640  for  Brucella  abortus. 
Antibiotic  treatment  with  doxycycline  and 
gentamicin was commenced.  
After  platelet  counts  recovered,  plasma-
exchange  was  stopped,  but  platelets  gradually 
dropped  to  96  x10
9/L  in  the  following  week, 
without significant changes in the hemoglobin level. 
Plasmapheresis was resumed on alternate days, with 
recovery  of      platelet  counts  to  normal  levels. 
Follow-up  blood  cultures  and  Brucella serology 
turned negative (figure 1). 
Discussion: Brucellosis is a major health problem 
in  many  parts  of  the  world,  particularly  in  the 
Mediterranean and the Middle East countries. It is a 
multisystem  disease  with  a  broad  spectrum  of 
clinical  manifestations.  Hematological Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
abnormalities  ranging  from  a  fulminant state  of 
disseminated  intravascular  coagulopathy  to  subtle 
hemostatic  alterations  have  been  reported  in 
Brucella infection.  Mild  anemia  and  leucopenia 
have  been  frequently  associated  with  acute 
brucellosis, but pancytopenia and thrombocytopenia 
are  less  frequent.  Thrombocytopenia  during  the 
clinical course of brucellosis presents an incidence 
varying from 1% to 8% of cases in adults.
8
The  clinical  picture  of  TTP  consists  of  a 
prodromal phase, a virus-like disease occurring in 
up to 40% of patients. About 60% of patients have 
neurologic disturbances, 90% initially have purpura 
and fever is constantly observed. Anemia is often 
severe  with  hemoglobin  levels  of  7-9  g/dl,  renal 
involvement is present in 90%, with renal failure in 
40-80% of patients. 
Advances  in recent  years  have  delineated  the 
molecular  mechanisms  of  acquired and  hereditary 
TTP and many of the atypical cases of Hemolytic 
Uremic  Syndrome  (HUS).  These  studies  have 
clearly  demonstrated  that  the  syndrome  of 
thrombotic  microangiopathy  encompasses  several 
distinct  molecular  defects.  TTP  has  been  
recognized to result from a profound deficiency of 
the  VWF  (von  Willebrand  factor)  cleaving 
metalloprotease  ADAMTS13.  Up  to  50%  of  the 
cases  of  atypical  HUS have  been  associated  with 
complement  dysregulation,  due  to  mutations  or 
autoantibodies  of  complement  factor  H,  serine 
protease  factor  I  or  membrane  cofactor  protein 
CD46.
9 Although each  disorder  may present  with 
the characteristic constellation of features, there is 
substantial  overlapping,  making  it  difficult  to 
distinguish these disorders solely based on clinical 
manifestations. Clinical diagnosis of TTP and HUS 
not based on pathophysiology or molecular defect is 
quite  variable  and  has  contributed  to  confusing 
literature.
Until  the  introduction  of  plasma  exchange 
therapy in the 1970's, TTP was almost universally 
fatal. Plasmapheresis is considered the mainstay of 
therapy,  removing  unusually  large  VWF  (UL-
VWF)  and  antibodies  against  the  VWF  cleaving 
metalloprotease on one hand, and replenishing the 
metalloprotease levels on the other.
Bell  et  al  reported  on  the  efficiency  of  this 
treatment that led to a notable decrease in mortality 
rates from near 100% to less than 10%.
1
Among other causes of TTP, various infections 
have been implicated, although an infectious agent 
has  not  been  always  isolated.  Other 
communications  have  emphasized  the  association 
between  rising  titers  of  coxsackie  B and  CMV
infection  with  Mycoplasma  pneumoniae, 
Mycobacterium tuberculosis, Borrelia burgdorferi, 
Herpes  zoster,  Legionella  pneumophilia, 
Bacteroides,  vaccination  against  influenza and 
typhoid  fever  type  A  and  B  and  a  concurrent 
presentation of TTP. 
Review of the published literature revealed at
least 6 cases with brucellosis-associated thrombotic 
microangiopathy (Table 1).
Five  cases  occurred  in  urkey  and  1  in  Italy 
suggesting  that  brucellosis  is  endemic  in  the 
Mediterranean region. Common clinical features in 
all reported cases were anemia, thrombocytopenia 
and schistocytes on blood smear, while neurologic 
symptoms  and  renal  insufficiency  were  less 
frequent.  In  none  of  these  published  cases  had 
Table 1. Summary of reported cases.
Age 
(years) Gender Country Evidence for 
Brucella
Clinical 
features ADAMTS-13 Therapy Outcome Referen
ce
19 Male Italy Blood culture A, T, S ND Ab AW 2
11 Female Turkey Serology, BM 
calture A, T, S ND Ab AW 3
71 Male Turkey Serology, 
blood calture A, T, S, N ND
Ab, 
plasmapher
esis
AW 4
51 Male Turkey Serology A, T, S, N, 
R ND Ab, MPD, 
FFP AW 5
19 Female Turkey Serology, BM 
calture A, T, S, N ND
Ab, FFP, 
plasmapher
esis
AW 6
7 Female Turkey Serology, A, T, S ND Ab, MPD, 
FFP death 7
Ab–Antibiotics, N–Neurological symptoms, MPL–Methylprednisolone, S–Schiztocytes, FFP–Fresh Frozen Plasma, ND–Not Done, 
A–Anemia, AW–Alive and Well, T–Thrombocytopenia, R–Renal InsufficiencyMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
ADAMTS-13  activity  or  neutralizing  antibodies 
been  performed.  Four  of  the  patients  had  been 
treated  without  plasmapheresis,  and  3  of  them 
survived.  The  lack  of  renal  and  neurologic 
symptoms,  and  the  high  survival  rate  for  TTP 
without plasmapheresis, raises the question: "Is it a 
true TTP?".
The  patients  described  had  the  features  of 
microangiopathic  hemolytic  anemia,  and  the 
differential  diagnosis  was  TTP  or  disseminated 
intravascular  coagulation  (DIC).  Normal 
coagulation  tests  (prothrombin  time,  activated 
partial  thromboplastin  time,  fibrinogen  and 
fibrinogen  degradation  products)  excluded  the 
possibility of DIC. Unfortunately, at that time the 
assay  for  ADAMTS13  activity  and  neutralizing 
antibodies was not available, though it is today.
In  summary,  we  present  a  case  of  a  young 
woman  who  presented  with  TTP  after  an  acute 
illness with concomitant infection of two Brucella
strains:  Brucella  melitensis  and Brucella  abortus. 
We  hypothesize  that  cross-reactive  antibodies 
between Brucella antigens and  the  VWF-cleaving 
metalloprotease or direct assault of the endothelium 
by the bacteria are the basis to this rare association. 
Prompt  treatment  with  plasma  exchange  is  the 
mainstay for therapy and is indeed life-saving. As in 
other  cases  of  refractory  or  exacerbated  TTP, 
treatment of the infection is mandatory in order to 
establish a rapid and solid remission.
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